Giloralimab

格洛瑞利单抗

Report date: 2024/09/24 20:00:05

Base Information

Drug NameGiloralimab
Drug Alias NameABBV-927
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-CD40
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[10] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms
Inactive IndicationsHead and Neck NeoplasmsPancreatic NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A